[Clinical study of the effect of buflomedil on peripheral neuropathy in diabetic patients].
OBJECTIVE
To observe the effect of buflomedil on clinical symptom and nerve conduction velocity (NCV) of diabetic peripheral neuropathy patients.


METHODS
58 cases of diabetic patents with peripheral neuropathy were divided into diabetes group treated with buflomedil (DB) 100 mg.d-1 and diabetes control group (DP) treated with PGE1 200 micrograms.d-1. NCV was measured and peripheral nerve symtom was observed in two groups before treatment and after 2 weeks.


RESULTS
NCV and peripheral nerve symptom were obviously improved both in DB group and DP group (P < 0.01). The effective rate were respectively 80.0% and 89.3% in DB group and DP group. The diversity was no significant in DB group and DP group (P > 0.05).


CONCLUSIONS
buflomedil is an effective and safe drug for treating diabetic peripheral neuropathy patients.
Zhou
M
M
Department of Endocrinology, Xiangya Hospital, Central South University, Changsha 410008, China.
Lei
M X
MX
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D003929:Diabetic Neuropathies / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011759:Pyrrolidines / Q000627:therapeutic use*
D000317:Adrenergic alpha-Antagonists; D011759:Pyrrolidines; C010651:buflomedil